Concurrent human antibody and T <sub>H</sub> 1 type T-cell responses elicited by a COVID-19 RNA vaccine
Uğur Şahin(Johannes Gutenberg University Mainz), Özlem Türeci(Johannes Gutenberg University Mainz), Alexandra Kemmer-Brück(BioNTech (Germany)), Kena A. Swanson(Pfizer (United States)), Stefanie Bolte(BioNTech (Germany)), John L. Perez(AstraZeneca (France)), Ulrich Luxemburger(BioNTech (Germany)), Katalin Karikó(BioNTech (Germany)), Jakob Loschko(Pfizer (United States)), Corinna Rosenbaum(BioNTech (Germany)), Mark Cutler(Pfizer (United States)), Jasmin Quandt(BioNTech (Germany)), Kathrin U. Jansen(Pfizer (United States)), Philip R. Dormitzer(Boston Children's Hospital), Mathias Vormehr(BioNTech (Germany)), Rolf Hilker(Justus-Liebig-Universität Gießen), Alina Baum(Regeneron (United States)), Pei‐Yong Shi(The University of Texas Medical Branch at Galveston), Isabel Vogler(BioNTech (Germany)), Evelyna Derhovanessian(University of Tübingen), Ingrid L. Scully(Pfizer (United States)), Tania Palanche(BioNTech (Germany)), Christos A. Kyratsous(Regeneron (United States)), Ann-Kathrin Eller(BioNTech (Germany)), Martin Bexon(Bexon Clinical Consulting (United States)), Warren V. Kalina(Pfizer (United States)), Julian Sikorski(BioNTech (Germany)), Lena M. Kranz(BioNTech (Germany)), Alexander Muik(BioNTech (Germany)), Kristen E. Pascal(Regeneron (United States)), Boris Fischer(BioNTech (Germany)), Verena Lörks(BioNTech (Germany)), Daniel Maurus(MerLion Pharma (Germany)), Sebastian Brachtendorf(BioNTech (Germany)), Carsten Boesler(BioNTech (Germany)), David Cooper(Johns Hopkins University), Dirk Becker(BioNTech (Germany)), David Langer(Goethe University Frankfurt), Jan Grützner(BioNTech (Germany)), Armin Schultz(Clinical Research Services), Marie-Cristine Kühnle(BioNTech (Germany)), Camila R. Fontes-Garfias(University of Rochester)
Cited by 67
Related Papers
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
|New England Journal of Medicine|2020|15.7k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
mRNA-based therapeutics — developing a new class of drugs
|Nature Reviews Drug Discovery|2014|2.4k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k